Controversies in the use of insulin analogues

Expert Opinion on Biological Therapy

Volumn 11, Issue 2, 2011, Pages 199-209

  Werner, Haim ^a   Weinstein, Doron ^a   Yehezkel, Einat ^a   Laron, Zvi ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

cancer; detemir; glargine; IGF I; insulin; insulin analogues

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; PIG INSULIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALIGNANT NEOPLASTIC DISEASE; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREGNANCY DIABETES MELLITUS; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RISK FACTORS;

EID: 78651377520     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.540233     Document Type: Review

References (48)

1. Hagedorn HC, Norman Jensen B, Krarup NB. Wodstrup I. Protamine insulinate. JAMA 1936;106:177-80
2. Scott DA, Fisher AM. Crystalline insulin. Biochem J 1935;29:1048-54
3. Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Hosp (Copenh) 1946;1:60-73
4. Brange J. The new era of biotech insulin analogues. Diabetologia 1997;40:S48-53
5. Dideriksen LH, Jorgensen LN, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 1992;41:143A
6. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54
7. Brems DN, Alter LA, Beckage MJ, et al Altering the association properties of insulin by amino acid replacement. Protein Eng 1992;5:527-33
8. Barlocco D. Insulin Glulisine. Aventis pharma. Curr Opin Investig Drugs 2003;4:1240-4
9. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000;59:253-60
10. Lepore M, Pampanelli S, Fanelli C, et al Pharmacokinetics and pharmacodynamics of subcutaneous injecting of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
11. Kurtzhals P, Havelund S, Jonassen I, et al Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312:725-31
12. Hamilton-Wessler M, Ader M, Dea M, et al Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 1999;42:1254-63
13. Butler PC. Insulin glargine controversy: a tribute to the editorial team at diabetologia. Diabetes 2009;58:2427-8
14. Hemkens LG, Grouven U, Bender R, et al Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44
15. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-13
16. Jonasson JM, Ljung R, Talback M, et al Insulin glargine use and short term incidence of malignancies-a population based follow up study in Sweden. Diabetologia 2009;52:1745-54
17. Colhoun HM. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-65
18. Rosemstock J, Fonseca V, McGill JB, et al Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009:52:1971-73
19. Mannucci E, Monami M, Balzi D, et al Doses of insulin and its analogues and cancer occurrence in insulin treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
20. Home PD, Lagarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-506
21. Forjanic-Klapproth J, Home PD. Progression of retinopathy with insulin glargine or NPH-a multi-trial analysis. Diabetologia 2001;44 (Suppl):1103
22. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6
23. Neumann E, Frei E, Funk D, et al Native albumin for targeted drug delivery. Exp Opin Drug Deliv 2010;7:915-25
24. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin determir: a meta analysis. Diabetologia 2009;52:2507-12
25. Singh SR, Ahmad F, Lal A, et al Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta analysis. Can Med Assoc J 2009;180:385-97
26. Kurtzhals P, Schaffer L, Sorensen A, et al Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
27. Laron Z. Insulin-like growth factor-1: a growth hormone. Mol Pathol 2001;54:311-16
28. Laron Z. IGF-1 and insulin as growth hormones. In: LeRoith D, Goode J, Bock G, editors, Biology of IGF-1: its interaction with insulin in health and malignant states. John Wiley & Sons Ltd, Chichester, UK; 2004. p. 58-63
29. Bahr MT, Kolter G, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997;320:259-65
30. Eckardt K, May C, Koenen M, Eckel J. IGF-I receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007;50:2534-43
31. Sciacca L, Cassarino MF, Genua M, et al Insulin analogues differently activate insulin rceptor isoforms and post-receptor signalling. Diabetologia 2010;53:1743-53
32. Weinstein D, Simon M, Yehezkel E, et al Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-9
33. Staiger K, Hennige AM, Staiger H, et al Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007;39:65-7
34. Yehezkel E, Weinstein D, Simon M, et al Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 2010;53:2667-75
35. Shukla A, Grisouard J, Ehemann V, et al Analysis of signaling pathwaysrelated to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009;16:429-41
36. Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010;116:73-8
37. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008;114:38-44
38. Shukla A, Enzmann H, Mayer D. Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. Arch Physiol Biochem 2009;115:119-26
39. Stammberger I, Bube A, Durchfeld-Meyer B, et al Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002;21:171-9
40. Holleman F, Gale EAM. Nice insulins, pity about the evidence. Diabetologia 2007;50:1783-90
41. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer-An unsubstantiated allegation. Diabetes Technol Therap 2009;11:473-6
42. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-708
43. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006;8:611-20
44. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause celebre? Int J Clin Pract 2010;64:628-36
45. Gale EAM. Insulin glargine and cancer: another side of the story? Lancet 2009;374:521
46. Giovannucci E, Harlan DM, Archer MC, et al Diabetes and cancer-a consensus report. Diabetes Care 2010;33:1674-83
47. Banting FG, Best CH, Collip JB, et al Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-6
48. Whittingham JL, Havelund S, Jonassen I. Crystal structure of prolonged-acting insulin with albumin-binding properties. Biochemistry 1997;36:2826-31